Valeant shares are down 6 percent in early trading on Friday following an announcement that it will sever ties with controversial mail-order pharmacy Philidor RX Services, LLC. Separately on Friday, Bill Ackman gave a conference call about Valeant.

Here’s a look at what four Wall Street firms have to say about the impact the move will have on Valeant shareholders.

Bank of America

Analyst Sumant Kulkami believes the financial impact of the decision will be minimal for Valeant and predicts that “VRX’s diverse business mix, durable asset base, and low product concentration risk position VRX to generate solid cash flow and de-lever to its goal of below 4x adj. EBITDA by the end of 2016.”

The firm maintains its Buy rating and $173 price objective.

JP Morgan

Analyst Chris Schott believes…

Click here to continue reading

Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!